{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T01:11:07Z","timestamp":1773882667780,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s12185-023-03701-z","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T17:02:15Z","timestamp":1706806935000},"page":"327-333","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Nelarabine-containing salvage therapy and conditioning regimen in transplants for pediatric T-cell acute lymphoblastic leukemia and lymphoma"],"prefix":"10.1007","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0203-1954","authenticated-orcid":false,"given":"Masato","family":"Yanagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamoru","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Mitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Seki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyoshi","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"3701_CR1","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373:1541\u201352.","journal-title":"N Engl J Med"},{"issue":"5","key":"3701_CR2","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/bjh.12442","volume":"162","author":"DT Teachey","year":"2013","unstructured":"Teachey DT, Hunger SP. Predicting relapse risk in childhood acute lymphoblastic leukaemia. Br J Haematol. 2013;162(5):606\u201320.","journal-title":"Br J Haematol"},{"key":"3701_CR3","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","volume":"33","author":"CH Pui","year":"2015","unstructured":"Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33:2938\u201348.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3701_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood.2019001557","volume":"135","author":"DT Teachey","year":"2020","unstructured":"Teachey DT, O\u2019Connor D. How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children. Blood. 2020;135(3):159\u201366.","journal-title":"Blood"},{"key":"3701_CR5","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","volume":"30","author":"SP Hunger","year":"2012","unstructured":"Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children\u2019s oncology group. J Clin Oncol. 2012;30:1663\u20139.","journal-title":"J Clin Oncol"},{"key":"3701_CR6","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1200\/JCO.20.00256","volume":"38","author":"KP Dunsmore","year":"2020","unstructured":"Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, et al. Children\u2019s oncology group AALL0434: a phase III randomized clinical trial testing nelarabine in lymphoblastic leukemia. J Clin Oncol. 2020;38:3282\u201393.","journal-title":"J Clin Oncol"},{"key":"3701_CR7","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/bjh.14017","volume":"173","author":"B Burkhardt","year":"2016","unstructured":"Burkhardt B, Mueller S, Khanam T, Perkins SL. Current status and future directions of T-lymphoblastic lymphoma in children and adolescents. Br J Haematol. 2016;173:554\u20139.","journal-title":"Br J Haematol"},{"key":"3701_CR8","first-page":"3363","volume":"27","author":"B Burkhardt","year":"2009","unstructured":"Burkhardt B, Reiter A, Landmann E, Lang P, Lassay L, Dickerhoff R, et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the Berlin\u2013Frankfurt\u2013Muenster group. Ann Hematol. 2009;27:3363\u20139.","journal-title":"Ann Hematol"},{"key":"3701_CR9","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2015.59","volume":"29","author":"C Eckert","year":"2015","unstructured":"Eckert C, Hagedorn N, Sramkova L, Mann G, Panzer-Gr\u00fcmayer R, Peters C, et al. Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment. Leukemia. 2015;29:1648\u201355.","journal-title":"Leukemia"},{"key":"3701_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","volume":"27","author":"P Bader","year":"2008","unstructured":"Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM study group. J Clin Oncol. 2008;27:377\u201384.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3701_CR11","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1172\/JCI111514","volume":"74","author":"B Ullman","year":"1984","unstructured":"Ullman B, Martin DW. Specific cytotoxicity of arabinosylguanine toward cultured T lymphoblasts. J Clin Invest. 1984;74(3):951\u20135.","journal-title":"J Clin Invest"},{"issue":"3","key":"3701_CR12","first-page":"1008","volume":"45","author":"DS Shewach","year":"1985","unstructured":"Shewach DS, Daddona PE, Ashcraft E, Mitchell BS. Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts. Cancer Res. 1985;45(3):1008\u201314.","journal-title":"Cancer Res"},{"key":"3701_CR13","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1182\/blood-2003-01-0317","volume":"102","author":"CO Rodriguez Jr","year":"2003","unstructured":"Rodriguez CO Jr, Stellrecht CM, Gandhi V. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood. 2003;102:1842\u20138.","journal-title":"Blood"},{"key":"3701_CR14","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","volume":"23","author":"SL Berg","year":"2005","unstructured":"Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the children\u2019s oncology group. J Clin Oncol. 2005;23:3376\u201382.","journal-title":"J Clin Oncol"},{"key":"3701_CR15","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1200\/JCO.2007.14.1986","volume":"26","author":"V Gandhi","year":"2008","unstructured":"Gandhi V, Tam C, O\u2019Brien S, Jewell RC, Rodriguez CO Jr, Lerner S, et al. Phase I trial of nelarabine in indolent leukemias. J Clin Oncol. 2008;26:1098\u2013105.","journal-title":"J Clin Oncol"},{"key":"3701_CR16","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/bjh.14874","volume":"179","author":"CM Zwaan","year":"2017","unstructured":"Zwaan CM, Kowalczyk J, Schmitt C, Bielorai B, Russo MW, Woessner M, et al. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study. Br J Haematol. 2017;179:284\u201393.","journal-title":"Br J Haematol"},{"key":"3701_CR17","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/ajh.25957","volume":"95","author":"A Candoni","year":"2020","unstructured":"Candoni A, Lazzarotto D, Ferrara F, Curti A, Lussana F, Papayannidis C, et al. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoma. A CAMPUS ALL study. Am J Hematol. 2020;95:1466\u201372.","journal-title":"Am J Hematol"},{"key":"3701_CR18","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1365-2141.2010.08236.x","volume":"150","author":"LA Commander","year":"2010","unstructured":"Commander LA, Seif AE, Insogna IG, Rheingold SR. Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed\/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma. Br J Haematol. 2010;150:345\u201351.","journal-title":"Br J Haematol"},{"issue":"2","key":"3701_CR19","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/bjh.13771","volume":"174","author":"MR Luskin","year":"2016","unstructured":"Luskin MR, Ganetsky A, Landsburg DJ, Loren DJ, Porter D, Nasta SD, et al. Nelarabine, cyclophosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma. Br J Haematol. 2016;174(2):332\u20134.","journal-title":"Br J Haematol"},{"key":"3701_CR20","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1007\/s12185-020-02962-2","volume":"112","author":"T Kumamoto","year":"2020","unstructured":"Kumamoto T, Goto H, Ogawa C, Hori T, Deguchi T, Araki T, et al. FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan children\u2019s cancer group. Int J Hematol. 2020;112:720\u20134.","journal-title":"Int J Hematol"},{"key":"3701_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29901","volume":"69","author":"JA Whitlock","year":"2022","unstructured":"Whitlock JA, Malvar J, Dalla-Pozza L, Goldberg JM, Silverman LB, Ziegler DS, et al. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008\u2013002 NECTAR). Pediatr Blood Cancer. 2022;69: e29901.","journal-title":"Pediatr Blood Cancer"},{"key":"3701_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/ajh.24947","volume":"93","author":"Y Abaza","year":"2018","unstructured":"Abaza Y, Kantarjian HM, Faderl S, Jabbour E, Jain N, Thomas D, et al. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol. 2018;93:91\u20139.","journal-title":"Am J Hematol"},{"key":"3701_CR23","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3701_CR24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"3701_CR25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/ajh.26144","volume":"96","author":"K Morita","year":"2021","unstructured":"Morita K, Jain N, Kantarjian H, Taahashi K, Fang H, Konopleva M, et al. Outcome of T-cell acute lymphoblastic leukemia\/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. Am J Hematol. 2021;96:589\u201398.","journal-title":"Am J Hematol"},{"issue":"2","key":"3701_CR26","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1200\/JCO.2000.18.2.340","volume":"18","author":"SM Davies","year":"2000","unstructured":"Davies SM, Ramsay NK, Klein JP, Weisdorf DJ, Bolwell B, Cahn JY, et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol. 2000;18(2):340\u20137.","journal-title":"J Clin Oncol"},{"key":"3701_CR27","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1002\/pbc.25602","volume":"62","author":"M Kato","year":"2015","unstructured":"Kato M, Ishida H, Koh K, Inagaki J, Kato K, Goto H, et al. Comparison of chemotherapeutic agents as a myeloablative conditioning with total body irradiation for pediatric acute lymphoblastic leukemia: a study from the pediatric ALL working group of the Japan society for hematopoietic cell transplantation. Pediatr Blood Cancer. 2015;62:1844\u201350.","journal-title":"Pediatr Blood Cancer"},{"issue":"15","key":"3701_CR28","first-page":"3352","volume":"55","author":"CU Lambe","year":"1995","unstructured":"Lambe CU, Averett DR, Paff MT, Reardon JE, Wilson JG, Krenitsky TA. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res. 1995;55(15):3352\u20136.","journal-title":"Cancer Res"},{"key":"3701_CR29","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1200\/JCO.1998.16.11.3607","volume":"16","author":"V Gandhi","year":"1998","unstructured":"Gandhi V, Plunkett W, Rodriguez CO Jr, Nowak BJ, Du M, Kisor M, et al. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J Clin Oncol. 1998;16:3607\u201315.","journal-title":"J Clin Oncol"},{"key":"3701_CR30","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1200\/JCO.2001.19.8.2142","volume":"19","author":"V Gandhi","year":"2001","unstructured":"Gandhi V, Plunkett W, Weller S, Du M, Ayres M, Rodriguez CO Jr, et al. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. J Clin Oncol. 2001;19:2142\u201352.","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03701-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-023-03701-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03701-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T06:25:49Z","timestamp":1718605549000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-023-03701-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["3701"],"URL":"https:\/\/doi.org\/10.1007\/s12185-023-03701-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]},"assertion":[{"value":"21 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest or sources of funding to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}